Akari Therapeutics (NASDAQ:AKTX) Issues Earnings Results

Akari Therapeutics (NASDAQ:AKTX) posted its earnings results on Monday. The biopharmaceutical company reported ($2.68) earnings per share (EPS) for the quarter, reports.

Akari Therapeutics Price Performance

Shares of AKTX stock opened at $5.15 on Wednesday. The stock’s 50 day simple moving average is $8.91 and its 200 day simple moving average is $17.94. Akari Therapeutics has a twelve month low of $4.56 and a twelve month high of $63.20.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. LADENBURG THALM/SH SH assumed coverage on shares of Akari Therapeutics in a report on Monday, January 5th. They set a “buy” rating and a $40.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Akari Therapeutics in a report on Wednesday, January 21st. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Akari Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $101.33.

Hedge Funds Weigh In On Akari Therapeutics

An institutional investor recently bought a new position in Akari Therapeutics stock. Armistice Capital LLC acquired a new position in Akari Therapeutics PLC (NASDAQ:AKTX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned 5.95% of Akari Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 5.06% of the company’s stock.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.